Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-Label, Assessor-Blind, Noninferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

Next Previous
Trial Profile

A Phase 3, Randomized, Open-Label, Assessor-Blind, Noninferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liprotamase (Primary) ; Pancreatic enzymes
  • Indications Cystic fibrosis; Exocrine pancreatic insufficiency
  • Focus Registrational; Therapeutic Use
  • Acronyms SOLUTION
  • Sponsors Anthera Pharmaceuticals

Most Recent Events

  • 02 Nov 2017 According to an Anthera Pharmaceuticals media release, data from this trial will be presented at the 31st annual North American Cystic Fibrosis Conference (NACFC). Dr Michael Konstan is a lead investigator of this trial.
  • 19 May 2017 Status changed from active, no longer recruiting to completed.
  • 15 May 2017 According to an Anthera Pharmaceuticals media release, RESULT trial builds upon data from this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top